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Background: Immediately following immunoablation and hematopoietic stem cell transplantation (IA-HSCT) for MS
a median decrease in brain volume of 3.2 % over 2.4 months occurs. After 2 years, rates of atrophy are comparable
to normal volunteers. Potential impact of atrophy on cognition was evaluated by examining performance on the
Paced Auditory Serial Addition Test (PASAT) pre- and post-IA-HSCT.
Methods: Twenty-three individuals with rapidly progressing/poor prognosis MS underwent high dose IA-HSCT.
Individuals completed the 3” PASAT at baseline and 6/12/18/24/30/36 months post-procedure.
Results: Mean decline in performance between baseline and 6-months occurred, though it was not statistically
significant. Minor declines were offset by an overall trend for improvement over time. The largest (non-significant)
cognitive gains were between months 30 and 36. Neither level of impairment at baseline, nor demographic
variables, influenced likelihood of improvement. No relationship between changes in cognition and changes
in volumes was detected, likely secondary to small sample size.
Conclusions: While an initial decline in cognition was noted 6 months post-IA-HSCT, there were no lasting
negative effects of treatment given the overall trend for improvement. Initial cognitive decline and marked
volume loss are likely secondary to acute toxic effects of chemotherapy. Gains in cognition noted over 36 months
suggest long-term follow-up is essential.
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Although advances in the therapeutic treatment of MS
have improved remarkably over the last several years,
current therapies are not curative. Rather, pharmaco-
logical treatments simply slow the progression of the
disease. Given that MS is an autoimmune disease treat-
ments aim to address the immunological aspects of the
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(http://creativecommons.org/publicdomain/zetransplantation (IA-HSCT) has been postulated as a
potential tool to treat a number of autoimmune dis-
eases [1, 2]. A few groups of researchers across the
globe have initiated the use of IA-HSCT procedures
in individuals with MS in hopes of halting disease
progression [3, 4]. The treatment is quite aggressive
and thus the selection criteria for inclusion in these
trials have been restricted to those with rapidly pro-
gressing MS and poor prognosis.
The Ottawa Hospital MS Clinic has completed a study
evaluating the impact of IA-HSCT on MS. Of the 23 in-
dividuals to undergo the procedure, no new attacks orle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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have been followed extensively and their progress has
been monitored in multiple ways, including neuroimag-
ing studies. This data has revealed that the IA-HSCT
procedure results in brain atrophy occurring at a signifi-
cantly greater rate than is expected on the basis of nat-
ural disease progression. For a more detailed discussion
on the atrophy observed, please see Lee et al. 2016 [7].
Atrophy has also been noted by other research groups
[8–10] and various explanations have been postulated to
explain the volume loss including: a selection bias for
patients with aggressive disease and potentially faster
rates of atrophy; long-term consequences of previous
disease activity on tissue integrity; “pseudoatrophy” from
reductions in edema (at least during the first year); and
finally, neurotoxicity of the chemotherapy conditioning
regimen [10]. In an attempt to address this issue our
group examined atrophy in 9 secondary progressive MS
patients compared to a patient with non-CNS non-
Hodgkin’s lymphoma (NHL) who underwent a compar-
able IA-HSCT procedure [11]. Volume loss exceeded
change in T2 lesion volume by 2- to 20-fold. Acute atro-
phy was not explained by resolution of edema. Both the
MS group and the NHL patient showed a median 3.2 %
volume loss over a median of 2.4 months. The compar-
able rates of atrophy suggest that volume loss was not
related to edema resolution, but rather to the toxicity of
therapy (which among other agents consisted of cyclo-
phosphamide, busulfan, and steroids); a known conse-
quence of such treatment.
The impact of this decrease in brain volume on cogni-
tion has been evaluated by our group in 7 of the 23 indi-
viduals who underwent the IA-HSCT procedure [12].
Results from a large battery of neuropsychological tests
(apart from the PASAT results reviewed here) revealed a
decline in executive functioning at 2 months post-
procedure. However, in those four individuals who com-
pleted 24-month follow-up, performance returned to
baseline levels. Thus, despite a decline in cognition in
the early period following treatment, with temporal dis-
tance from the HSCT procedure, cognition returned to
baseline levels in those who completed the follow-up.
No significant correlations were found between cognitive
decline and change in imaging variables or stem cell
dosage; although the small sample size may have masked
any such relationships. Results from this study, though
quite preliminary, are promising and suggest that immu-
noablation and HSCT may have no lasting deleterious
effects on cognition.
The current study aims to further examine patterns
of cognitive change in all 23 individuals from the
Ottawa Hospital MS Clinic who underwent the IA-
HSCT procedure. Whereas only the small subset of 7
individuals completed full neuropsychological batteries,all 23 participants underwent serial evaluation with the
Paced Auditory Serial Addition Test (PASAT). As such,
we were able to evaluate the impact of IA-HSCT on in-
formation processing speed (IPS) and working memory
(WM) using the PASAT. Testing took place at baseline
(i.e. before the IA-HSCT procedure) and every 6 months
for a period of 3 years.
The PASAT is the only cognitive measure in the
Multiple Sclerosis Functional Composite (MSFC) [13].
Although there are clear limitations to the PASAT [14]
and alternative measures such as the Symbol Digit
Modalities Test have been discussed, [15, 16] the PASAT
remains a measure that is highly sensitive to cognitive
impairment and has become widely used in MS research.
It has become a common outcome measure in clinical
trials and, in particular, has become a useful tool to moni-
tor cognitive change over time. Longitudinal change in
PASAT scores do not correlate with change in EDSS
scores, [17] but PASAT performance does correlate with
imaging parameters such as DTI measures, [18] MTR in
normal appearing white matter, [19, 20] brain activation
using fMRI, [21, 22] atrophy, [23] and gadolinium en-
hancement (a marker of active inflammatory activity),
[24] as well as electrophysiological measures such as P3
ERP [25]. Thus, this measure is an easily administered
clinical tool that can be a marker for underlying disease
progression. Higher scores on the PASAT are associated
with better quality of life outcomes, demonstrating that it
also has relevance to outcomes important to people suffer-
ing from MS [26, 27]. Rosti and colleagues (2007) [28]
found that the PASAT was able to detect deterioration in
cognition after only 1 year, but this phenomenon was
found only in those individuals with MS who were already
cognitively impaired at baseline (i.e., cognitively intact in-
dividuals with MS did not change over that time interval).
One of the complications when using the PASAT in serial
testing is its susceptibility to practice effects [13, 28]. None-
theless, this can be controlled statistically (see below).
Given our previous work which documented cognitive
decline immediately post-IA-HSCT in some individuals,
[12] it was hypothesized that a similar decline in PASAT
scores would be found at the 6 month mark with im-
provement expected at all other time points. MRI scans
were obtained in conjunction with the cognitive testing to
examine the potential correlation between volume loss
and cognition. Our past preliminary work has shown little
relationship between volume and cognitive variables early
after transplant, but the current study evaluated this po-
tential relationship over a longer follow-up interval [12].
Methods
Participants
This study was approved by the Ottawa Hospital Re-
search Ethics Board and informed consent was obtained.
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who failed to respond to routine therapy (i.e. progression
or continued relapses or worsening MRI after at least
1 year of therapy with interferon-β1, glatiramer acetate,
mitoxantrone, or other conventional dose immunosup-
pressive drug therapy) were enrolled. High risk of pro-
gression was defined as ≥5 relapses in the first 2 years of
disease or attainment of a Functional System (FS) Score
of at least 3 (or findings consistent with a FS of 3) affect-
ing pyramidal/cerebellar subscores within 5 years of on-
set. If a patient had previously received a cytotoxic agent
(mitoxantrone, cyclophosphamide, etc.) they must have
had normal bone marrow morphology and cytogenetics
before being considered eligible for this study. MRI brain
scans satisfied the MRI criteria of Paty or Fazekas for
the diagnosis of MS. None of the subjects had evidence
of hepatic inflammation or fibrosis. In the 23 subjects en-
rolled baseline EDSS ranged from 1.5 to 6.5 (mean = 4.87
(1.40)). Education ranged from high school to graduate
school with the median value being equivalent to college
level. Age ranged from 23 to 44 years (mean = 32.65 (5.82)
years). Of the 23 subjects, 12 were diagnosed with
relapsing-remitting MS and 11 with secondary progressive
MS. Those with primary progressive MS were excluded.
Procedure and measures
The study was a tri-center phase II efficacy study of the
role of intensive immunosupression and autologous
HSCT on the natural history of MS. Participants under-
went stem cell mobilization with IV cyclophosphamide
(4.5 g/m2) and 10 days of granulocyte colony-stimulating
factor (10 μg/kg/day) followed by stem cell collection
using peripheral vein leukopheresis. All stem cell grafts
were CD34 selected and cryopreserved until transplant-
ation. Immunoablation was accomplished using cyclo-
phosphamide (200 mg/kg), dose-adjusted IV busulfan
(maximum 16 mg/kg) and IV rabbit antithymocyte
globulin (5 mg/kgSolumedrol was administered concur-
rently with ATG to reduce the risk of hypersensitivity re-
actions. Participants did not receive further MS-disease
modifying drugs or experimental therapy after IA-HSCT.
Participants underwent MRI scans with pre- and post-
gadolinium enhanced T1-weighted and dual spin-echo
(Proton Density/T2-weighted) sequences at baseline and
then serially every 6 months until 36 months post-IA-
HSCT. T1-weighted pre-contrast scans were used to calcu-
late volumes of GM, WM, and regional structures. At the
same time points as the MRI, subjects completed the 3”
PASAT. Note that a run-in procedure was not used for the
PASAT. However, see below for the manner in which this
was controlled statistically. Two participants did not
complete the follow-up interval past 18 months as they
underwent an unproven therapy for disease progression
against the advice of their treating neurologist, andinclusion of their data would have made it more chal-
lenging to interpret findings in the context of the
treatment of interest.
Data analysis
The GM and WM volumes, normalized for subject head
size, were calculated with FSL-SIENAX (cross-sectional
variation of Structural Image Evaluation, using Normalisa-
tion, of Atrophy) [29]. Subcortical gray matter structures
were segmented and their volumes were calculated with
FSL-FIRST (FMRIB’s Integrated Registration and Seg-
mentation Tool: http://www.fmrib.ox.ac.uk/fsl/first) [30].
Volumes of cortical and other subcortical structures were
calculated with Freesurfer v5.1 (http://surfer.nrm.mgh.har-
vard.edu/) [31, 32].
Because group comparisons of tests scores can mask
significant individual differences (as can practice effects
due to prior task exposure), the reliable change index
(RCI) (corrected for practice) was calculated for the
PASAT in order to assess an individual’s change over
time. A variation of the RCI was used that included an
adjustment for practice effects that result from serial
testing [33]. Note that practice effects were accounted
for up to 12 months given that research has shown stability
in practice after the third PASAT retest session [14, 34].
RCI ¼ time 2−time 1ð Þ−practice
SEDiff
 
SEdiff is the standard error of the difference which
represents the spread of distribution of change scores
expected had no change occurred. Given that, to the
best of our knowledge, there is no published data for the
3” PASAT which provides means and standard devia-
tions for multiple administrations, the practice effect was
calculated by taking the mean difference between the
second and first administration of the 3” PASAT (as well
as between the third and second administration) for a
group of healthy controls (from a different study in our
lab) who received multiple administrations up to a week
apart. For a more specific examination of the demo-
graphics of this control sample, please see Walker et al.
2012 [35]. The RCI scores were considered to be statisti-
cally significant and reliable at 90 % confidence intervals
if the degree of change fell outside ±1.64.
Chi-square analysis was conducted to determine if
those who were impaired at baseline were more or less
likely to show improvement over time compared to
those who were not impaired at baseline.
Analysis of variance (ANOVA) was performed to deter-
mine if demographic variables (such as age, gender, and
education) explained the differences noted between those
who show improvement in their performance from base-
line to 36 months post-IA-HSCT and those who do not.
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performed to determine if PASAT RCI values (e.g. base-
line to 6 months, 6 to 12 months, etc.) correlated with
change in brain volume (i.e. difference scores) of the
cortical and subcortical structures.
Results
Reliable Change Index (RCI) analyses
Please see Table 1 for RCI values per subject.
On average, there was a decline in RCI values between
performance at baseline and performance at 6-month
follow-up (mean RCI =−0.13) (see Fig. 1).
This value, although reflective of decline, does not
reach statistical significance. An RCI value must
exceed +/- 1.64 in order to be considered significant.Table 1 RCI values per subject
* missing data
RCI significant improvement
RCI significant declineFollowing the 6-month mark, a trend for improve-
ment was noted until 24 months, although this trend
did not reach statistical significance. There was a de-
cline noted at 30-months but examination of the raw
scores revealed a trend for stability, with the mean
decline being driven by one outlier who declined
significantly. The largest cognitive gains took place
between months 30 and 36, but again not to a statis-
tically significant degree.Chi-square analyses
Subjects’ impairment status at baseline (cognitively im-
paired vs. cognitively intact) did not impact whether they
declined, remained stable, or improved over time.
Fig. 1 3” PASAT Mean RCI Values Over Time
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There were no differences in demographics (age, gender,
education) between those who showed reliable improve-
ment and those who did not.
Correlational analyses
Change in PASAT performance did not correlate sig-
nificantly with the change in percent normalized
brain volume (PNBV), percent cortical grey matter
volume (PGMV), or percent white matter volume
(PWMV) at any time point (see Table 2 for mean
percent normalized brain volumes over time).
Similarly, there was no relationship between change in
PASAT performance and change in any of the cortical
and subcortical structure volumes at any time point. For
a more comprehensive examination of the observed
MRI changes please see Lee et al. 2016 [7].
Discussion
Consistent with the hypothesis, we were able to docu-
ment a slight trend toward the expected decline in
PASAT performance in the initial period post-IA-HSCT
given that there was a mean RCI decline between base-
line and 6 months. Similarly, there was a much more en-
couraging trend for improvement over the longer
follow-up interval. It is important to note however, that
these findings did not reach statistical significance when
group means were considered. The lack of significance
cannot be attributed to changes associated with practice
effects given that the RCI analyses take this into account;
nor are these findings likely to be attributed to small
sample size given that these analyses were at the level ofTable 2 Mean percent normalized brain volumes over time
Baseline 6 m 12 m
Percent Normalized Brain Volume 100.00 97.68 (1.58) 97.44
Percent Grey Matter Volume 100.00 94.12 (2.59) 94.89
Percent White Matter Volume 100.00 100.66 (1.90) 99.29the individual. Six individuals demonstrated significant
improvement during at least one of the time periods
evaluated but several more exhibited more subtle im-
provements. The lack of statistical significance overall
suggests that the changes in WM and IPS experienced
post-IA-HSCT are subtle. This is consistent with others
who describe only subtle changes in cognition associated
with chemotoxicity and the resolution of initial declines
as time progresses post-treatment [36, 37]. In our previ-
ous report, we outline why we believe that chemotoxicity
played a significant role in the increased rate of atrophy
[11]. The neurotoxic effects of chemotherapy have been
well documented in the literature [36, 38] and thus, in
addition to the atrophic changes, this is also likely the
reason for the initial transient decline in cognition noted
here. Current findings mirror what was documented by
our group when examining performance on a subset of
participants on a full neuropsychological evaluation [12].
Indeed, it was found that cognition declined briefly in
the initial period post-procedure and returned to base-
line levels by the 24-month follow-up. The current study
evaluated cognition at more frequent time intervals, and
examination of the mean RCI values (see Fig. 1) suggests
that cognition returns to baseline levels by 12 months.
Thus, the latter half of the first year post-IA-HSCT
appears to be a critical period with regard to cogni-
tive gains. The IA-HSCT procedure did not differen-
tially impact cognition based upon cognitive status
before the procedure, nor did demographic variables
influence outcome.
After 12 months, there is a trend for ongoing subtle
cognitive gains (with the exception of the outlier influen-
cing performance at 30 months). Does the fact that
PASAT values at 36 months follow-up exceed initial
baseline levels (after accounting for practice) argue for
neuronal repair? Clearly, it is too soon to make a claim
like this, but results are promising and warrant further
study. If cognition is improved over baseline levels then
perhaps the IA-HSCT procedure does not simply halt
disease progression, but fosters repair (i.e. the cognitive
findings may be a marker for this potential improved
pathology). Certainly past research has confirmed that
PASAT performance correlates with imaging markers of
pathology [18, 19, 21, 22, 24]. Nine of the 23 individuals
undergoing this study have demonstrated improvement
in neurological function (i.e. EDSS improvement of 1 or
more) compared to baseline levels, [6] so this would18 m 24 m 30 m 36 m
(1.90) 97.31 (1.72) 97.25 (1.75) 96.26 (2.20) 96.45 (2.57)
(2.98) 95.28 (2.79) 94.09 (2.71) 93.78 (4.20) 93.50 (5.18)
(3.12) 98.97 (2.60) 99.83 (3.62) 98.60 (3.37) 98.59 (3.36)
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ity. Further investigations must occur in order to test
this notion and draw any firm conclusions.
The lack of association between PASAT performance
and atrophy measures is consistent with our past prelimin-
ary findings, [12] but inconsistent with the research litera-
ture that typically demonstrates a correlation between
PASAT performance and neuroimaging [18, 19, 21, 22, 24].
The primary reason for the lack of relationship is likely that
the sample size was insufficient. A larger sample size would
garnermore statistical power to detect such a relationship.
The small sample size is a function of the nature of this
particular study. Enrollment criteria was quite restrictive
and was limited to those with rapidly progressive disease
who had not responded well to established therapies.
Although the current IA-HSCT procedure appears quite
promising with regard to halting disease progression and
with regard to these preliminary cognitive findings, it re-
mains a procedure that should be considered only after
other options have been exhausted given the risks with
which it is associated. A multi-centre trial holds the most
promise with regard to enrollment of larger numbers, and
indeed, discussions are underway. In such a circumstance,
greater statistical power may allow us to detect the ex-
pected relationship between change in cognition and
changes in brain volumes.
An additional limitation of this study is the lack of a
control group. Attempts were made to obtain an appro-
priate control; however, we were unsuccessful. We
attempted to approach individuals undergoing bone
marrow transplant for other indications besides MS (i.e.
haematological cancers). However, recruitment proved
to be extremely difficult due to the fact that individuals
undergoing such procedures are typically extremely ill.
Their motivation to participate in research is low and
those who are more motivated are more likely to volun-
teer for research targeting their own health condition
(i.e. they have no impetus to contribute to MS research
given that it does not relate to them directly).
Conclusions
The results of this study are clearly preliminary, but hold
some promise. Initial subtle declines in cognition post-
IA-HSCT are presumably due to chemotoxic effects, but
these subtle declines are reversible with scores improv-
ing over time and eventually exceeding initial baseline
levels. Thus, any negative impact on cognition of the IA-
HSCT procedure appears to be only minor and tempor-
ary and does not appear to cause any lasting damage to
the CNS. Results at 36 months highlight the necessity of
long-term follow-up. Future research should attempt to
replicate these findings in larger sample sizes via multi-
centre initiatives. The question of possible neural repair
should also be evaluated.Abbreviations
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